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Diffuse large B cell lymphoma (DLBCL) ac-
counts  for  30–40%  of  all  human  lymphoid 
malignancies (Anderson et al., 1998; Coiffier, 
2001). Gene expression profiling has identi-
fied distinct DLBCLs subtypes that differ in 
their oncogenic mechanisms. The two main 
categories  are  activated  B  cell–like  (ABC) 
DLBCL, and germinal center B cell–like (GCB) 
DLBCL (Alizadeh et al., 2000; Rosenwald 
et al., 2002, 2003; Savage et al., 2003; Wright 
et  al.,  2003).  The  ABC  subtype  shows  the 
most aggressive clinical behavior and a gene 
expression signature that corresponds to the 
profile of B lymphocytes stimulated through 
their antigen receptor (B cell receptor). Its 
key feature is the activation of the NF-B sig-
naling pathway (Alizadeh et al., 2000; Davis 
et al., 2001).
NF-B proteins are ubiquitously expressed 
transcription factors (Hayden and Ghosh, 2008). 
A large variety of physiological stimuli can rap-
idly activate NF-B through a canonical IB 
kinase (IKK)–dependent pathway to induce ex-
pression  of  target  genes  that  include  potent   
survival factors, cell cycle regulators, and growth-
promoting cytokines. ABC-DLBCL cells exhibit 
uncontrolled and stimulus-independent activa-
tion of the IKK–NF-B pathway (Davis et al., 
2001; Lam et al., 2005) and small molecule IKK 
inhibitors are selectively toxic to ABC but not 
to GCB-type DLBCL cells in vitro (Davis et al., 
2001; Lam et al., 2005). These findings marked 
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Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma in humans. 
The aggressive activated B cell–like (ABC) subtype of DLBCL is characterized by constitutive 
NF-B activity and requires signals from CARD11, BCL10, and the paracaspase MALT1 for 
survival. CARD11, BCL10, and MALT1 are scaffold proteins that normally associate upon 
antigen receptor ligation. Signal-induced CARD11–BCL10–MALT1 (CBM) complexes couple 
upstream events to IB kinase (IKK)/NF-B activation. MALT1 also possesses a recently 
recognized proteolytic activity that cleaves and inactivates the negative NF-B regulator 
A20 and BCL10 upon antigen receptor ligation. Yet, the relevance of MALT1 proteolytic 
activity for malignant cell growth is unknown. Here, we demonstrate preassembled CBM 
complexes and constitutive proteolysis of the two known MALT1 substrates in ABC-DLBCL, 
but not in germinal center B cell–like (GCB) DLBCL. ABC-DLBCL cell treatment with a 
MALT1 protease inhibitor blocks A20 and BCL10 cleavage, reduces NF-B activity, and 
decreases the expression of NF-B targets genes. Finally, MALT1 paracaspase inhibition 
results in death and growth retardation selectively in ABC-DLBCL cells. Thus, our results 
indicate a growth-promoting role for MALT1 paracaspase activity in ABC-DLBCL and 
suggest that a pharmacological MALT1 protease inhibition could be a promising approach 
for lymphoma treatment.
© 2009 Ferch et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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treatment with a MALT1 protease inhibitor blocks A20 and 
BCL10 cleavage, reduces NF-B activity and decreases the 
expression of the NF-B targets BCL-XL, IL-6, and IL-10. 
Finally, MALT1 paracaspase inhibition results in ABC-DLBCL 
cell death and growth retardation. These results indicate a 
growth-promoting role for MALT1 paracaspase activity, spe-
cifically in ABC-DLBCL cells and highlight MALT1 prote-
ase activity as a potential target for pharmacological treatment 
of ABC-DLBCL.
RESULTS AND DISCUSSION
Constitutive and selective CBM complex assembly  
and MALT1 protease activity in ABC-DLBCL cells
The MALT1 protease is physiologically activated upon anti-
gen receptor triggering and subsequent assembly of the CBM 
complex (Coornaert et al., 2008; Rebeaud et al., 2008). As 
ABC-DLBCL cells require constitutive signals from the CBM 
complex for survival and expansion (Ngo et al., 2006), we 
first investigated whether CBM complexes might be preas-
sembled in ABC-DLBCL. To this end, we used well-charac-
terized ABC- or GCB-DLBCL cell lines (Davis et al., 2001; 
Ngo et al., 2006; Lenz et al., 2008) and immunoprecipitated 
BCL10 in the absence of stimulation and upon stimulation 
with PMA + Iono. We then tested the association of BCL10 
with MALT1 or CARD11 by immunoblotting. BCL10 and 
MALT1 bind constitutively to each other in all DLBCL cell 
lines tested (Fig. 1 A). However, stimulus-independent tri-
molecular association of BCL10/MALT1 with CARD11 was 
only detected in the ABC-DLBCL cell lines OCI-Ly3, HBL1, 
U2932, and OCI-Ly10, but not in the GCB-DLBCL lines 
SUDHL-4, SUDHL-6, and BJAB (Fig. 1 A), although PMA + 
Iono treatment could induce CBM complexes in all cell lines. 
These results indicate constitutive CBM complex formation 
selectively in ABC-DLBCL.
To study whether the preassembled CBM complexes 
in ABC-DLBCL cells might be associated with constitutive 
MALT1 protease activity, we next analyzed the processing of 
the two known MALT1 substrates A20 and BCL10 (Fig. 1, 
B–D). MALT1 can cleave A20 after arginine 439, generating 
the short-lived A20-p37 fragment that is rapidly degraded by 
the proteasome (Coornaert et al., 2008). A20 is an NF-B 
target gene, and as such it is part of a negative feedback loop 
(Chen et al., 2006; Hayden and Ghosh, 2008). In contrast to 
the GCB-DLBCL cells, the ABC-DLBCL cells exhibit high 
expression levels of A20 (Fig. 1 B). Intriguingly, the A20-p37 
cleavage product, detected by a monoclonal antibody to the 
C  terminus  of  A20,  is  constitutively  present  in  all  ABC- 
DLBCL  cell  lines.  Moreover,  proteasome  inhibition  with 
MG132 to block A20-p37 degradation (Coornaert et al., 2008) 
further  augmented  A20-p37  concentrations  in  these  cells. 
Likewise, lymphoma cell treatment with PMA + Iono to ex-
ogenously induce MALT1 protease activity (Coornaert et al., 
2008; Rebeaud et al., 2008) also increased A20-p37 concen-
trations above constitutive levels. To test whether MALT1 is 
responsible for A20 cleavage in DLBCL cells, we selectively 
blocked MALT1 protease function without affecting MALT1 
the NF-B pathway as an attractive target for ABC-DLBCL 
therapy. Yet, as the IKK–NF-B axis is ubiquitously expressed 
and contributes to cellular homeostasis in multiple tissues, a 
general IKK–NF-B inhibition is associated with significant 
toxicities in vivo, and thus not ideal for lymphoma treatment 
(Baud and Karin, 2009).
Lymphocyte-specific  IKK  and  NF-B  activation  in 
response to normal antigen receptor signaling requires the   
immune cell–restricted CARD11–BCL10–MALT1 (CBM) 
complex consisting of the adapter proteins CARD11 (also 
called CARMA1) and BCL10 and the paracaspase MALT1 
(Ruland and Mak, 2003; Thome, 2004). Antigen receptor li-
gation induces a rapid assembly of the CBM complex at the 
plasma membrane by recruiting the constitutively interacting 
proteins BCL10 and MALT1 to CARD11. The CBM com-
plex is then responsible for a further recruitment of IKKs and 
other factors into distinct microdomains to trigger context-
specific IKK activation for NF-B–mediated lymphocyte sur-
vival and proliferation (Thome, 2004; Rawlings et al., 2006).
Oncogenic gain of function mutations of CARD11 that en-
force NF-B activation are recurrently detected in ABC-
DLBCL biopsies (Lenz et al., 2008; Compagno et al., 2009; 
Kato et al., 2009). Additional genetic events are thought to in-
duce aberrant CBM activity in other cases, as CARD11, BCL10, 
and MALT1 are all required for the survival and expansion of 
ABC-DLBCL cells (Ngo et al., 2006). Thus, a selective interfer-
ence with CBM signaling could be a promising strategy for 
ABC-DLBCL treatment (Ngo et al., 2006) that would not in-
hibit the IKK–NF-B pathway in nonlymphoid cells.
As CARD11 and BCL10 are scaffold proteins without 
enzymatic function, they are not ideal drug targets. How-
ever, the paracaspase MALT1 contains a caspase-like domain 
(Uren et al., 2000) that possesses inducible arginine-specific 
cysteine protease activity, in addition to protein–protein in-
teraction  motifs  (Coornaert  et  al.,  2008;  Rebeaud  et  al., 
2008). The MALT1 paracaspase activity is physiologically ac-
tivated upon antigen receptor stimulation or after PMA and 
ionomycin (PMA + Iono) treatment and requires CARD11- 
and BCL10-mediated MALT1 oligomerization (Coornaert 
et al., 2008; Rebeaud et al., 2008). Two MALT1 substrates 
have been identified. Activated MALT1 cleaves its binding 
partner BCL10 and the ubiquitin-editing enzyme A20, an in-
hibitor of the IKK–NF-B pathway (Beyaert et al., 2000) that 
emerges as an important tumor suppressor in the B cell lin-
eage (Compagno et al., 2009; Kato et al., 2009; Malynn and 
Ma, 2009; Schmitz et al., 2009). MALT1 protease activity is 
responsible for optimal NF-B activation and IL-2 produc-
tion in antigen receptor–stimulated T cells, suggesting that 
this activity is key for full physiological lymphocyte activa-
tion (Coornaert et al., 2008). Whether MALT1 protease 
activity  plays  a  functional  role  in  malignant lymphocyte 
growth is currently unknown.
Here, we demonstrate that ABC-DLBCL cells, but not 
GCB-DLBCL cells, possess constitutively assembled CBM 
complexes and that A20 and BCL10 are continuously and 
selectively processed in ABC-DLBCL cells. Lymphoma cell JEM VOL. 206, October 26, 2009  2315
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Figure 1.  Constitutive CBM complex assembly and MALT1 protease activity in ABC-DLBCL. (A) ABC-DLBCL or GCB-DLBCL cell lines were left 
untreated or stimulated with PMA + Iono for 20 min. Lysates were immunoprecipitated with anti-BCL10 and immunocomplexes were analyzed for the 
presence for CARD11, BCL10, or MALT1 by immunoblotting (top). Total cellular contents of CARD11, BCL10, MALT1, or -actin were analyzed in lysates 
without immunoprecipitation (bottom). (B–D) Immunoblot analysis for the presence of A20 (B) or BCL10 (C and D) cleavage products. (B) A20 processing. 
Individual cell lines were either left untreated, stimulated for 2 h with PMA + Iono or incubated for 2 h in the presence of MG132; zVRPR-fmk was added 
30 min before stimulation where indicated. Filled arrow, full length A20; open arrow, A20p37 cleavage product; *, nonspecific band. -Actin blotting 
served as a loading control. (C) BCL10 processing. Lysates from nonstimulated ABC-DLBCL or GCB-DLBCL cell lines were immunoblotted with anti-BCL10. 
(D) DLBCL cells were left untreated or treated with zVRPR-fmk. Filled arrow, full length BCL10; open arrow, BCL105 fragment. The MALT1 immunoblot 
indicates equal loading. Data are one representative of three (A and D) or four (B and C) independent experiments.2316 MALT1 PROTEASE FUNCTION IN DLBCL | Ferch et al.
substantially reduced BCL-XL protein levels in all ABC-
DLBCL cells (Fig. 2 C). In contrast, the GCB-DLBCL cell 
lines were either lacking constitutive BCL-XL expression 
(SUDHL-4 and SUDHL-6) or, as in the case of BJAB, BCL-XL 
expression was not sensitive to MALT1 inhibition.
A recent study has shown that the NF-B activity triggers 
the production of the cytokines IL-6 and IL-10 in ABC-
DLBCL, which contribute to malignant cell growth in an 
autocrine manner (Lam et al., 2008). We therefore investi-
gated whether the secretion of these factors might be MALT1 
protease dependent. The ABC-DLBCL lines OCI-Ly3, HBL1, 
and OCI-Ly10 produce substantial amounts of IL-6, which 
was significantly inhibited by zVRPR-fmk (Fig. 2 D). More-
over, the ABC-DLBCL lines OCI-Ly3, U2932, and OCI-
Ly10 secreted IL-10, which was also sensitive to MALT1 
protease inhibition (Fig. 2 D). The IL-10 production by the 
GCB-DLBCL line BJAB was, in contrast, not significantly 
reduced by MALT1 protease inhibition. Collectively, we can 
conclude that MALT1 paracaspase inhibition also impairs ex-
pression of NF-B targets such as BCL-XL, IL-6, and IL-10 
specifically in ABC-DLBCL cells.
MALT1 protease activity is required for survival  
and proliferation of ABC-DLBCL cells
Knockdown experiments with siRNAs have shown that the 
presence of the MALT1 protein is required for ABC-DLBCL 
cell growth (Ngo et al., 2006). Even a prolonged incubation 
of GCB-DLBCL cells with zVRPR-fmk did not affect the 
survival of these tumor cells (Fig. 3 A) excluding general cyto-
toxic effects. Yet, the frequency of viable ABC-DLBCL cells 
declined significantly and continuously over time in all four 
ABC-DLBCL lines compared with untreated controls.
To determine the consequences of zVRPR-fmk treatment 
on DLBCL cell proliferation, the cells were labeled with CFSE 
and division was tracked by CFSE dilution measurement in the 
viable population (Fig. 3 B). Similar to cell viability, the GCB-
DLBCL cell division rate was unaffected by MALT1 protease 
inhibition. In contrast, zVRPR-fmk treatment significantly im-
paired the proliferation of all ABC-DLBCL cell lines. Thus, the 
MALT1 protease inhibitor zVRPR-fmk reduces both survival 
and division selectively in ABC-DLBCL cells but has no appar-
ent cytotoxic effects on GCB-DLBCL cells.
To quantify the effects of MALT1 paracaspase inhibition 
on overall ABC-DLBCL cell growth, we finally compared the 
absolute cell numbers in the presence or absence of the MALT1 
antagonistic peptide (Fig. 3 C). Intriguingly, after 1 wk of treat-
ment, the combined effects on cell survival and proliferation 
reduced the total ABC-DLBCL cell numbers between 35% 
(U2932) and 95% (OCILy10; Fig. 3 C). Together, these data 
reveal a vital role for MALT1 protease activity in ABC-
DLBCL cell growth, which can be blocked by pharmaco-
logical means.
Concluding remarks
A hallmark of the aggressive ABC subtype of DLBCL is the 
constitutive activation of the NF-B pathway that occurs 
protein expression. To this end, we used the recently devel-
oped antagonistic tetrapeptide zVRPR-fmk, which is an ir-
reversible inhibitor of MALT1 protease activity in vitro and 
in cultured cells (Rebeaud et al., 2008). Treatment of ABC-
DLBCL cells with zVRPR-fmk strongly inhibited both 
constitutive as well as PMA + Iono induced A20 processing, 
indicating that the MALT1 paracaspase is constitutively ac-
tive in these cells and responsible for A20 cleavage.
Next, we studied the proteolysis of BCL10, which is present 
in both the ABC and GCB DLBCL cell lines (Fig. 1, A and C). 
BCL10 cleavage by MALT1 generates the BCL105 fragment 
that lacks the five carboxy-terminal amino acids from BCL10 
and migrates slightly faster in gels (Rebeaud et al., 2008). The 
BCL105 fragment was constitutively present in all ABC- 
DLBCL lines, but not in GCB-DLBCL cells (Fig. 1 C), al-
though PMA + Iono treatment induced BCL10 cleavage in 
the GCB-DLBCL line BJAB (Fig. 1 D). The MALT1 inhibi-
tor zVRPR-fmk blocked both the constitutive processing of 
BCL10 in the ABC-DLBCL cells (Fig. 1 D), as well as PMA + 
Iono–induced BCL10 processing in the GCB-DLBCL line, 
again indicating that MALT1 is responsible for BCL10 cleav-
age. Together, these results indicate that the MALT1 paracas-
pase is preactivated and uncoupled from antigenic stimulation 
in ABC-DLBCL, but not in GCB-DLBCL cells.
MALT1 paracaspase inhibition reduces NF-B activity  
in ABC-DLBCL cells
MALT1-mediated proteolysis is required for full NF-B acti-
vation and optimal production of the NF-B–dependent 
factor IL-2 in antigen receptor–stimulated T cells (Coornaert   
et al., 2008; Rebeaud et al., 2008). In line with previously 
published data (Davis et al., 2001), the ABC-DLBCL lines 
OCI-Ly3, HBL1, U2932, and OCI-Ly10 exhibit constitutive 
NF-B activity that is much higher than in GCB-DLBCL 
lines (Fig. 2 A). Intriguingly, cell treatment with the MALT1 
antagonistic peptide zVRPR-fmk specifically reduced NF-B 
DNA-binding in ABC-DLBCL cells, indicating that the high 
constitutive NF-B activity is in part controlled by MALT1 
protease function. To further characterize the effects of MALT1 
protease inhibition on NF-B signaling in ABC-DLBCL, we 
separated nuclear from cytoplasmic extracts before and after 
zVRPR-fmk treatment. Consistent with high NF-B DNA 
binding activity, all ABC-DLBCL cell lines exhibit profound 
levels of the c-Rel and RELA subunits in the nucleus (Fig. 2 B). 
Cell treatment with the MALT1 inhibitor reduced nuclear 
c-Rel levels in all ABC-DLBCL lines substantially, although it 
only marginally affected RELA. These results further indicate 
that MALT1 protease activity is required for the full constitu-
tive NF-B signal in ABC-DLBCL cells. These data are in line 
with the known selective requirement of MALT1 in the con-
trol of c-Rel in B cells (Ferch et al., 2007).
To study the consequences of the MALT1 protease in-
hibition on gene expression, we next investigated the expres-
sion of the NF-B-controlled antiapoptotic factor BCL-XL 
in DLBCL cells as a marker of NF-B activity (Chen et al., 
2000). Treatment with the MALT1 inhibitor zVRPR-fmk JEM VOL. 206, October 26, 2009  2317
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Figure 2.  Inhibition of MALT1 protease activity interferes with NF-B DNA binding in ABC-DLBCL. (A) Gel-mobility-shift assay of nonstimu-
lated ABC-DLBCL or GCB-DLBCL cells left untreated or incubated with zVRPR-fmk for 48 h. Nuclear extracts were analyzed by electrophoretic mobility 
shift assay for NF-B DNA-binding activity. NF-B signals were quantified by densitometry and are expressed below the respective lanes as values rela-
tive to untreated cells. (B) Immunoblot analysis of the abundance of c-Rel and RELA in cytoplasmatic (C) and nuclear (N) extracts of ABC-DLBCL cells left 
untreated or incubated with zVRPR-fmk for 48 h. Western blotting for the nuclear marker protein Lamin B confirms successful separation into cytoplas-
mic and nuclear extracts and equal nuclear protein loading. (C) Immunoblot analysis of BCL-XL expression in untreated or zVRPR-fmk–treated (48 h) ABC-
DLBCL or GCB-DLBCL cell lines. -Actin blot serves as a loading control. (D) Concentrations of secreted IL-6 and IL-10 were determined in the 
supernatants of untreated or zVRPR-fmk–treated (48 h) ABC-DLBCL and GCB-DLBCL cell lines by ELISA. Data from one out of three (A, C, and D) or four 
(B) independent experiments with similar results are shown.
through various genetic events (Alizadeh et al., 2000; Lenz   
et al., 2008; Compagno et al., 2009; Kato et al., 2009). Al-
though the respective upstream mechanism differs between 
individual cases, the CBM complex is required for ABC-
DLBCL cell survival and expansion (Ngo et al., 2006; Lenz   
et al., 2008; Compagno et al., 2009). As markers for constitu-
tive MALT1 paracaspase activity, we observed selective and 
stimulus-independent proteolysis of A20 and BCL10 in ABC-
DLBCL. The functional role of processed BCL10 in lym-
phomagenesis is still unclear. Yet, MALT1-mediated cleavage 
of the tumor suppressor A20 might be functionally relevant, 
as A20 can limit malignant B cell growth (Kato et al., 2009; 
Malynn and Ma, 2009). All ABC-DLBCL lines that we used 
(OCI-Ly3, HBL1, U2932, and OCI-Ly10) are heterozygous 
at the TNFAIP3 gene locus, which encodes for A20, and 
thus contain one WT allele (Compagno et al., 2009). Consis-
tently, all lines express full-length A20 that is prone to prote-
olysis. Although MALT1 activity does not deplete the total 2318 MALT1 PROTEASE FUNCTION IN DLBCL | Ferch et al.
Figure 3.  MALT1 protease inhibition selectively affects survival and proliferation of ABC-DLBCL cells. (A) Cell viability. ABC-DLBCL or GCB-
DLBCL cell lines either left untreated or cultured in the presence of zVRPR-fmk for the indicated times were stained with Annexin V and propidium iodide, 
and viability was subsequently determined by flow cytometry. Depicted is the mean percentage of viable cells ± SD normalized to day 0 from one repre-
sentative experiment out of three. *, P < 0.05; **, P < 0.01. (B) Cell proliferation. DLBCL cell lines (5 × 104) labeled with CFSE and cultured in the absence 
(shaded histograms) or presence of zVRPR-fmk (open histograms) for the indicated times; cell division was tracked by flow-cytometric analysis of CFSE 
fluorescence in 104 viable cells. Data are representative of three independent experiments. (C) Total cell numbers. ABC-DLBCL cell were cultured with our 
without zVRPR-fmk, and total viable cell numbers were counted at the indicated time points. Depicted is the percentage of absolute viable cell numbers ± 
SD after zVRPR-fmk treatment relative to untreated cells. Shown is the mean ± SD from three independent experiments.JEM VOL. 206, October 26, 2009  2319
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Coimmunoprecipitation. DLBCL cells were lysed in coimmunoprecipita-
tion buffer (0.2% Nonidet P40, 150 mM NaCl, 50 mM Hepes, pH 7.5, 
1 mM glycerol, 10 mM NaF, 8 mM -glycero-phosphate, 1 mM Na3VO4, and 
protease inhibitors). Immunoprecipitation was performed overnight at 4°C, 
and after incubation of sepharose beads (GE Healthcare) precipitates were 
boiled and analyzed by immunoblot.
Gel-mobility-shift assay. Nuclear extracts from 5 × 106 DLBCL cells were 
prepared using standard methods (Ferch et al., 2007). Concentrations were 
adjusted according to Bradford assay and nuclear protein extracts (2.5 µg) 
were incubated in 20-µl binding buffer (100 mM Tris, pH 7.5, 500 mM KCl, 
10 mM dithiothreitol and 1 µg poly (dI-dC)) with IRDye700-labeled, double-
stranded oligonucleotide probes (NF-B, 5-AGTTGAGGGGACTTT-
CCCAGGC–3). Upon electrophoretic separation on a 5% polyacrylamide 
gel, EMSAs were analyzed using Odyssey Infrared Imaging System (Licor 
Biosciences) and Software for densitometric quantification.
ELISA. ELISAs were performed using human IL-6 and IL-10 ELISA sets 
(BD) according to manufacturer’s protocol.
Statistics. P-values were determined by applying Student’s two-tailed t test 
for independent samples, assuming equal variances on all experimental data-
sets using the Microsoft excel t test calculator.
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cellular A20 content, it cleaves the A20 molecules in the 
direct  vicinity  of  activated  CBM  and  IKK  complexes 
(Coornaert et al., 2008). We hypothesize that these A20 
molecules are responsible for NF-B inhibition and growth 
control. Thus, paracaspase-mediated cleavage of A20 could 
be one mechanism of A20 inactivation in addition to the 
genomic mutations that are detected in other subsets of   
B cell lymphoma (Compagno et al., 2009; Kato et al., 2009; 
Schmitz et al., 2009).
Although additional functionally relevant MALT1 sub-
strates may exist, our report represents the first non–small in-
terfering RNA–based approach that targets a component of 
the CBM complex to study effects on malignant cell growth. 
We demonstrate that MALT1 paracaspase inhibition down-
regulates NF-B signaling and results in growth inhibition 
specifically in CBM/IKK-dependent ABC-DLBCL cells. 
MALT1 is the only known paracaspase in mammals, and pro-
teases are ideal targets for the development of small molecule 
inhibitors with several clinically successful examples (Turk, 
2006). MALT1-deficient mice exhibit mainly immunological 
defects, but are otherwise viable and healthy (Ruefli-Brasse   
et al., 2003; Ruland et al., 2003). Thus, the development of 
MALT1-specific small molecule protease inhibitors could 
lead to novel targeted therapeutics for lymphomas with aber-
rant MALT1 activity, which are expected to have limited 
toxic side effects in vivo.
MATERIALS AND METHODS
Cell culture and reagents. All cell lines were cultured as previously de-
scribed (Davis et al., 2001). In brief, OCI-Ly3 and OCI-Ly10 were main-
tained in Iscove´s modified essential medium with 20% heparinized human 
plasma,  penicillin,  streptomycin,  and  -mercaptoethanol.  HBL1,  U2932, 
SUDHL-4, SUDHL-6, and BJAB cell lines were maintained in RPMI 1640 
medium supplemented with 10% FCS, l-glutamine, penicillin, streptomycin, 
and -mercaptoethanol. The cell lines OCI-Ly3, HBL1, U2932, and OCI-
Ly10 have recently been shown to be hemizygous for TNFAIP3 (Compagno 
et al., 2009). Moreover, several cell lines harbor additional mutations in NF-B 
pathway components (OCI-Ly3, CARD11; OCI-Ly10, RANK; U2932, 
TAK1; Compagno et al., 2009). zVRPR-fmk (Alexis Biochemicals) was 
solved in ddH2O at a concentration of 75 µM throughout all experiments. 
MG132 and PMA + Iono (Sigma-Aldrich) were reconstituted in DMSO (fi-
nal DMSO concentration 0.1% or 0.01%, respectively).
Survival and proliferation assays. DLBCL cells were seeded in a density 
of 106 cells/ml in a 96-well plate and cultured in the absence or presence of 
zVRPR-fmk (75 µM), as previously described (Rebeaud et al., 2008). Cell 
viability was quantified by flow cytometry after Annexin V and propidium 
iodide (eBioscience) staining. Cell proliferation was determined by flow 
cytometry after CFSE (Sigma-Aldrich) staining. Data were analyzed with 
FlowJo software (Tree Star, Inc.) according to standard protocols.
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10 mM NaF, 1 mM NaVO4 and protease inhibitors (Calbiochem)). For frac-
tionation into cytoplasmic and nuclear extracts, lymphocytes were first lysed 
using Buffer A (0.2% Nonidet P40, 10 mM Hepes, pH 7.9, 10 mM KCl, 
0.1 mM EDTA, 0.1 mM EGTA, and protease inhibitors). Protein extracts of 
pelleted nuclei were generated using RIPA buffer (0.5 M Tris-HCl, pH 7.4, 
1.5 M NaCl, 2.5% deoxycholic acid, 10% Nonidet P40, 10 mM EDTA, 
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